4-Oxo-1,4-dihydropyridines as selective CB2 cannabinoid receptor ligands part 2: Discovery of new agonists endowed with protective effect against experimental colitis

Journal of Medicinal Chemistry

Volumn 55, Issue 20, 2012, Pages 8948-8952

  El Bakali, Jamal ^a   Gilleron, Pauline ^a   Body Malapel, Mathilde ^b   Mansouri, Roxane ^a   Muccioli, Giulio G ^c,d   Djouina, Madjid ^b   Barczyk, Amélie ^a   Klupsch, Frédérique ^a   Andrzejak, Virginie ^a   Lipka, Emmanuelle ^b   Furman, Christophe ^d   Lambert, Didier M ^c   Chavatte, Philippe ^a   Desreumaux, Pierre ^b   Millet, Régis ^a  

^a Faculté des Sciences Pharmaceutiques et Biologiques Université de Lille   (France)

^b UNIV LILLE   (France)

^c UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^d France Institut Pasteur de Lille   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 OXO 1,4 DIHYDROPYRIDINE; ANTIINFLAMMATORY AGENT; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR AGONIST; DIHYDROPYRIDINE DERIVATIVE; MESALAZINE; PROTECTIVE AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COLITIS; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DRUG SYNTHESIS; MOUSE; NONHUMAN;

ADAMANTANE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BINDING, COMPETITIVE; BLOOD PROTEINS; CHO CELLS; COLITIS; CRICETINAE; CRICETULUS; HUMANS; INTESTINAL ABSORPTION; LIGANDS; MICE; MICROSOMES, LIVER; PROTEIN BINDING; PYRIDINES; RADIOLIGAND ASSAY; RECEPTOR, CANNABINOID, CB2; STRUCTURE-ACTIVITY RELATIONSHIP; TRINITROBENZENESULFONIC ACID;

EID: 84867775246     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm3008568     Document Type: Article

References (19)

1. De Petrocellis, L.; Di Marzo, V. An Introduction to the Endocannabinoid System: From the Early to the Latest Concepts Best Pract., Res. Clin. Endocrinol. Metab. 2009, 23, 1-15
2. Izzo, A. A.; Sharkey, K. A. Cannabinoids and the Gut: New Developments and Emerging Concepts Pharmacol. Ther. 2010, 126, 21-38
3. Howlett, A. C.; Barth, F.; Bonner, T. I.; Cabral, G.; Casellas, P.; Devane, W. A.; Felder, C. C.; Herkenham, M.; Mackie, K.; Martin, B. R.; Mechoulam, R.; Pertwee, R. G. International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors Pharmacol. Rev. 2002, 54, 161-202
4. Sartor, R. B. Mechanisms of Disease: Pathogenesis of Crohns Disease and Ulcerative Colitis Nature Clin. Pract. Gastroenterol. Hepatol. 2006, 3, 390-407
5. Storr, M. A.; Keenan, C. M.; Zhang, H.; Patel, K. D.; Makriyannis, A.; Sharkey, K. A. Activation of the Cannabinoid 2 Receptor (CB2) Protects Against Experimental Colitis Inflammatory Bowel Dis. 2009, 15, 1678-1685
6. DArgenio, G.; Valenti, M.; Scaglione, G.; Cosenza, V.; Sorrentini, I.; Di Marzo, V. Up-Regulation of Anandamide Levels as an Endogenous Mechanism and a Pharmacological Strategy to Limit Colon Inflammation FASEB J. 2006, 20, 568-570
7. Massa, F.; Marsicano, G.; Hermann, H.; Cannich, A.; Monory, K.; Cravatt, B. F.; Ferri, G. L.; Sibaev, A.; Storr, M.; Lutz, B. The Endogenous Cannabinoid System Protects Against Colonic Inflammation J. Clin. Invest. 2004, 113, 1202-1209
8. Jamontt, J. M.; Molleman, A.; Pertwee, R. G.; Parsons, M. E. The Effects of Delta-Tetrahydrocannabinol and Cannabidiol Alone and in Combination on Damage, Inflammation and in Vitro Motility Disturbances in Rat Colitis Br. J. Pharmacol. 2010, 160, 712-723
9. Kimball, E. S.; Schneider, C. R.; Wallace, N. H.; Hornby, P. J. Agonists of Cannabinoid Receptor 1 and 2 Inhibit Experimental Colitis Induced by Oil of Mustard and by Dextran Sulfate Sodium Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 291, 364-371
10. Singh, U. P.; Singh, N. P.; Singh, B.; Price, R. L.; Nagarkatti, M.; Nagarkatti, P. S. Cannabinoid Receptor-2 (CB2) Agonist Ameliorates Colitis in IL-10(-/-) Mice by Attenuating the Activation of T Cells and Promoting their Apoptosis Toxicol. Appl. Pharmacol. 2012, 258, 256-267
11. 2 Receptors J. Mol. Med. (Berlin) 2008, 86, 925-936
12. Andrzejak, V.; Muccioli, G. G.; Body-Malapel, M.; El Bakali, J.; Djouina, M.; Renault, N.; Chavatte, P.; Desreumaux, P.; Lambert, D. M.; Millet, R. New FAAH Inhibitors Based on 3-Carboxamido-5-aryl-isoxazole Scaffold that Protect Against Experimental Colitis Bioorg. Med. Chem. 2011, 19, 3777-3786
13. Alhouayek, M.; Lambert, D. M.; Delzenne, N. M.; Cani, P. D.; Muccioli, G. G. Increasing Endogenous 2-Arachidonoylglycerol Levels Counteracts Colitis and Related Systemic Inflammation FASEB J. 2011, 25, 2711-2721
14. 2 Cannabinoid Receptor Ligands: Structural Insights into the Design of a Novel Inverse Agonist Series J. Med. Chem. 2010, 53, 7918-7931
15. Govaerts, S. J.; Hermans, E.; Lambert, D. M. Comparison of Cannabinoid Ligands Affinities and Efficacies in Murine Tissues and in Transfected Cells Expressing Human Recombinant Cannabinoid Receptors Eur. J. Pharm. Sci. 2004, 23, 233-243
16. For experimental procedure, see Supporting Information.
17. 2 Receptors Eur. J. Pharmacol. 2004, 495, 43-53
18. For experimental procedure, see Supporting Information.
19. Frost, J. M.; Dart, M. J.; Tietje, K. R.; Garrison, T. R.; Grayson, G. K.; Daza, A. V.; El-Kouhen, O. F.; Yao, B. B.; Hsieh, G. C.; Pai, M.; Zhu, C. Z.; Chandran, P.; Meyer, M. D. Indol-3-ylcycloalkyl Ketones: Effects of N1 Substituted Indole Side Chain Variations on CB(2) Cannabinoid Receptor Activity J. Med. Chem. 2010, 53, 295-315